Finch Therapeutics

40 articles with Finch Therapeutics

• 

  Clinical Catch-Up: November 8-12

  11/15/2021

  It was another busy week for clinical trial news. Here’s a look.
• 

  BioSpace Movers & Shakers, Nov. 12

  11/12/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Finch Therapeutics to Participate in Upcoming Investor Conferences

  11/11/2021

  Finch Therapeutics Group, Inc. today announced that Mark Smith, PhD, Chief Executive Officer, will participate virtually in two upcoming investor conferences: Jefferies London Healthcare Conference

• Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

  11/10/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, reported financial results for the third quarter ended September 30, 2021 and provided business updates.

• Finch Therapeutics Announces Transition of Chief Medical Officer

  11/10/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Zain Kassam, MD, MPH has elected to step down as Chief Medical Officer in order to return to Canada to attend to a family health matter.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

  10/12/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021.

• 

  BioSpace Movers & Shakers, Oct. 8

  10/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors

  10/5/2021

  Finch Therapeutics Group, Inc. today announced that Samuel Allen (Al) Hamood has joined Finch’s Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance

• 

  BioSpace Movers & Shakers, Sept. 10

  9/10/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer

  9/8/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced the appointment of Marc Blaustein as Chief Operating Officer.

• Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

• Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/10/2021

  Finch Therapeutics Group, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

• Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program

  8/10/2021

  Finch Therapeutics Group, Inc. today announced that Takeda Pharmaceutical Company Limited (“Takeda”) has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program.

• Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes

  6/28/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that it was added to the Russell 2000 and Russell 3000 Indexes as part of the 2021 Russell indexes annual reconstitution that took effect after the market close on June 25, 2021.

• Finch Therapeutics to Present at Upcoming Virtual Investor Conferences - May 28, 2021

  5/28/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will participate in two upcoming virtual investor conferences:

• Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

  5/13/2021

  Initiation of Phase 3 trial of CP101 for recurrent CDI and Phase 1 trial of CP101 for chronic hepatitis B virus expected in mid-2021; initiation of Phase 1 trial of FIN-211 in autism expected in H2 2021

• Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference

  5/6/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 2:45 pm ET.

• Finch Therapeutics Appoints Susan E. Graf to Board of Directors

  4/27/2021

  Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, announced that Susan E. Graf has joined Finch’s Board of Directors and will serve as Chair of the Audit Committee.

• 

  Money on the Move: March 17-23

  3/24/2021

  It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.